Cargando…

Association of inflammatory markers with the disease & mutation status in pancreatic cancer

BACKGROUND & OBJECTIVES: Inflammation has been studied to be an important contributory factor to carcinogenesis through pro-inflammatory markers such as interleukin (IL)-6 and C-reactive protein (CRP). Furthermore, K-ras mutation is an important genetic alteration in the pathogenesis of pancreat...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Nidhi, Gupta, Surabhi, Rashid, Sumaira, Saraya, Anoop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552386/
https://www.ncbi.nlm.nih.gov/pubmed/35859428
http://dx.doi.org/10.4103/ijmr.IJMR_2238_18
_version_ 1784806239429984256
author Singh, Nidhi
Gupta, Surabhi
Rashid, Sumaira
Saraya, Anoop
author_facet Singh, Nidhi
Gupta, Surabhi
Rashid, Sumaira
Saraya, Anoop
author_sort Singh, Nidhi
collection PubMed
description BACKGROUND & OBJECTIVES: Inflammation has been studied to be an important contributory factor to carcinogenesis through pro-inflammatory markers such as interleukin (IL)-6 and C-reactive protein (CRP). Furthermore, K-ras mutation is an important genetic alteration in the pathogenesis of pancreatic cancer. This study aimed to compare these inflammatory markers in pancreatic ductal adenocarcinoma (PDAC) with the diseased and healthy controls (HCs) and to check for any association between IL-6 and CRP serum levels with the disease status, survival and K-ras mutation status of PDAC patients. METHODS: The study included 135 PDAC, 25 chronic pancreatitis (CP) patients and 25 HCs. The serum levels of IL-6 and CRP were detected by enzyme-linked immunosorbent assay and K-ras mutations were detected by polymerase chain reaction-restriction fragment length polymorphism technique. RESULTS: The serum levels of both these markers were elevated in PDAC cases than that in HCs. High IL-6 levels and higher CRP levels were found to be associated with locally advanced disease, lymphatic invasion, metastasis and advanced stage of the PDAC. In patients with unresectable PDAC, higher IL-6 levels were found to be associated with the presence of K-ras mutations. INTERPRETATION & CONCLUSIONS: Higher IL-6 and CRP levels in patients with advanced PDAC suggest an important role of these inflammatory markers in tumour progression. Furthermore, the association of mutations in the K-ras gene with serum IL-6 indicates cross-talks that may contribute to the progression of the PDAC.
format Online
Article
Text
id pubmed-9552386
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-95523862022-10-12 Association of inflammatory markers with the disease & mutation status in pancreatic cancer Singh, Nidhi Gupta, Surabhi Rashid, Sumaira Saraya, Anoop Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Inflammation has been studied to be an important contributory factor to carcinogenesis through pro-inflammatory markers such as interleukin (IL)-6 and C-reactive protein (CRP). Furthermore, K-ras mutation is an important genetic alteration in the pathogenesis of pancreatic cancer. This study aimed to compare these inflammatory markers in pancreatic ductal adenocarcinoma (PDAC) with the diseased and healthy controls (HCs) and to check for any association between IL-6 and CRP serum levels with the disease status, survival and K-ras mutation status of PDAC patients. METHODS: The study included 135 PDAC, 25 chronic pancreatitis (CP) patients and 25 HCs. The serum levels of IL-6 and CRP were detected by enzyme-linked immunosorbent assay and K-ras mutations were detected by polymerase chain reaction-restriction fragment length polymorphism technique. RESULTS: The serum levels of both these markers were elevated in PDAC cases than that in HCs. High IL-6 levels and higher CRP levels were found to be associated with locally advanced disease, lymphatic invasion, metastasis and advanced stage of the PDAC. In patients with unresectable PDAC, higher IL-6 levels were found to be associated with the presence of K-ras mutations. INTERPRETATION & CONCLUSIONS: Higher IL-6 and CRP levels in patients with advanced PDAC suggest an important role of these inflammatory markers in tumour progression. Furthermore, the association of mutations in the K-ras gene with serum IL-6 indicates cross-talks that may contribute to the progression of the PDAC. Wolters Kluwer - Medknow 2022-01 /pmc/articles/PMC9552386/ /pubmed/35859428 http://dx.doi.org/10.4103/ijmr.IJMR_2238_18 Text en Copyright: © 2022 Indian Journal of Medical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Singh, Nidhi
Gupta, Surabhi
Rashid, Sumaira
Saraya, Anoop
Association of inflammatory markers with the disease & mutation status in pancreatic cancer
title Association of inflammatory markers with the disease & mutation status in pancreatic cancer
title_full Association of inflammatory markers with the disease & mutation status in pancreatic cancer
title_fullStr Association of inflammatory markers with the disease & mutation status in pancreatic cancer
title_full_unstemmed Association of inflammatory markers with the disease & mutation status in pancreatic cancer
title_short Association of inflammatory markers with the disease & mutation status in pancreatic cancer
title_sort association of inflammatory markers with the disease & mutation status in pancreatic cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552386/
https://www.ncbi.nlm.nih.gov/pubmed/35859428
http://dx.doi.org/10.4103/ijmr.IJMR_2238_18
work_keys_str_mv AT singhnidhi associationofinflammatorymarkerswiththediseasemutationstatusinpancreaticcancer
AT guptasurabhi associationofinflammatorymarkerswiththediseasemutationstatusinpancreaticcancer
AT rashidsumaira associationofinflammatorymarkerswiththediseasemutationstatusinpancreaticcancer
AT sarayaanoop associationofinflammatorymarkerswiththediseasemutationstatusinpancreaticcancer